BDSX
Biodesix, Inc. Common Stock
stockNASDAQ
biodesix develops and commercializes blood-based molecular diagnostic tests that advance the standard of care in oncology. our diagnostics help patients and their doctors make more informed decisions about treatment based on a patient's unique molecular profile. we're advancing precision medicine by helping physicians provide the right patient with the right treatment at the right time, and move patients to optimal treatment faster. we partner with pharmaceutical companies to develop tests that accelerate pipelines and bring effective therapies to market. our two commercialized tests, veristrat® & genestrat™, offer results in 72 hours. no tissue is required.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 27.33 | 2026-10-01 | -6.88% | 7.858 |
| 1M | 26.63 | 2026-09-08 | -4.43% | -0.701 |
| 3M | 20.15 | 2026-07-08 | +26.30% | 1.600 |
| 6M | 14.25 | 2026-04-08 | +78.60% | 1.214 |
| 1Y | 7.75 | 2025-10-08 | +228.39% | 0.947 |
| 2Y | 33.60 | 2024-10-08 | -24.26% | — |
| 5Y | 154.40 | 2021-10-08 | -83.52% | 0.848 |
Biodesix, Inc. Common Stock (NASDAQ:BDSX) stock price today is $25.45, and today's volume is 89,562. BDSX is down 3.671% today. The 30 day average volume is 103,232. BDSX market cap is $268.53M with 10.55M shares outstanding.